Determined to build the leading biotech player in a new R&D space, Steven Holtzman lines up $55M for the next stage at Decibel
There are no big pharmas or large cap biotechs building a pipeline of drugs for hearing loss. So Steven Holtzman wants to build a leading …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
